VYNE News and Press, VYNE Therapeutics Inc Com From 11/25/20

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Confere...

VYNE Therapeutics (VYNE) Q3 2020 Earnings Conference Call November 5, 2020 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conference Call Participants Car...

Foamix Pharmaceuticals Ltd (FOMX) Q3 2020 Earnings Conference Call November 5, 2020 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conference Call Partici...

VYNE Therapeutics (VYNE): Q3 Non-GAAP EPS of -$0.13 beats by $0.02; GAAP EPS of -$0.15 beats by $0.03.Revenue of $3.27M beats by $0.02M.Press Release For further details see: VYNE Therapeutics EPS beats by $0.02, beats on revenue

BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. “The launch of...

BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before th...

Vyne Therapeutics is executing well, successfully launching 2 differentiated dermatology products this year. Amzeeq Rx trends have exhibited 20% compounded growth since the economic shutdown in April. Newly launched rosacea treatment, Zilxi, already has high prescriber awareness a...

5 Penny Stocks To Watch Tomorrow It’s never a guarantee that penny stocks will always return thousands of percentage points. It’s also not a complete lock that all penny stocks will end in losses. What’s the difference between winning traders and losing trad...

VYNE Therapeutics ([[VYNE]] +4.3%) has announced a coverage update for its ZILXI topical foam, 1.5%, FDA approved minocycline product for use in rosacea for the treatment of inflammatory lesions in adults.Express Scripts has elected to cover ZILXI effective October 2, on Express Scripts'...

VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts Coverage Effective October 2, 2020 on Express Scripts National Preferred, Flex, and Basic Formularies PR Newswire BRIDGEWATER, N.J., Oct. 7, 2020 BRIDGEWATER, N.J. ...